FDA will issue new warnings about Multaq liver failure cases

Bloomberg News (1/14, Torsoli) reported that two patients taking the Multaq (dronedarone) heart treatment have suffered liver failure. ” Sanofi will inform doctors about liver function test results and injuries reported in patients treated with Multaq, including two cases of acute liver failure” according to a company spokesman. Multaq, “cleared for sale in 2009, treats atrial fibrillation, a rapid and irregular beating in the heart’s upper chambers affecting an estimated two million people in the US, according to the National Heart, Lung and Blood Institute.”